Daily non-political popular news in brief.

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia

11-15-2007 · EurekAlert!

Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia, the sixth leading cause of death in the United States.

Keywords: cethromycin, achieves, endpoints, pivotal, phase, iii, trial, treatment, pneumonia, achieve, endpoint

« Previous | Next »

Similar news on "Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia":

Ovation further advances development pipeline with new phase III epilepsy study
09-04-2007 · EurekAlert!
Ovation Pharmaceuticals is initiating a pivotal Phase III clinical trial for clobazam, a unique 1,5 benzodiazapine with significant anticonvulsant properties, as adjunctive treatment for patients with Lennox-Gastaut syndrome, one of the most severe forms of childhood epilepsy that frequently persists into adulthood. LGS is a rare and debilitating form of epilepsy. Clobazam represents one of five CNS launches Ovation expects over the next five years.
Similar news · Read more »
New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10-15-2007 · EurekAlert!
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
Similar news · Read more »
Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
05-02-2007 · EurekAlert!
Phase III clinical trial shows effectiveness of once-yearly treatment for postmenopausal osteoporosis.
Similar news · Read more »
Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
05-16-2007 · EurekAlert!
Clinical trial data for Perforomist Inhalation Solution will be presented at ATS on May 20, 2007. Data from Phase III pivotal trial demonstrates safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD.
Similar news · Read more »
Eculizumab is well-tolerated and shows significant improvement in PNH patients (Ph III)
12-09-2006 · EurekAlert!
Eculizumab, a MAb drug, appeared safe and well-tolerated, and provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH) in a Phase 3 open-label, 52 weeks of treatment trial. PNH is a rare and life-threatening form of hemolytic anemia and acquired genetic blood disorder, and patients lack naturally-occurring complement inhibitors on the surface of their red blood cells.
Similar news · Read more »
Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
01-10-2007 · EurekAlert!
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Similar news · Read more »
GSK announces launch of largest ever Phase III trial in lung cancer treatment
06-05-2007 · EurekAlert!
GlaxoSmithKline today announced final results of a Phase II clinical trial of its investigational Antigen-Specific Cancer Immunotherapeutic MAGE-A3 in non small cell lung cancer. Final trial analysis showed a 27 percent reduction in the relative risk of cancer recurrence following surgery, compared to placebo. GSK also announced today the launch of a Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment.
Similar news · Read more »
Accentia issues update on blinded results in phase 3 of SinuNase for chronic sinusitis
08-15-2007 · EurekAlert!
Based on an interim blinded analysis of the first group of the more than 80 patients who have now completed the trial at 16 weeks, the study has shown improvement in polyposis by endoscopy in about 50 percent of patients (N=43) and improvement in sinus inflammation by CT scan in approximately 50 percent of patients (N=23). Moreover, 50 percent of patients with objective evidence of improvement have achieved the primary endpoint of complete resolution of cardinal symptoms.
Similar news · Read more »
NIH announces phase III clinical trial of creatine for Parkinson's disease
03-22-2007 · EurekAlert!
The NIH National Institute of Neurological Disorders and Stroke today is launching a large-scale clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance. The potential benefit of creatine for PD was identified by Parkinson's researchers through a new rapid method for screening potential compounds.
Similar news · Read more »
First multinational study of Tocilizumab reports in
06-15-2007 · EurekAlert!
Nearly half -- 43.9 percent -- of rheumatoid arthritis patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50 percent improvement in symptoms at 24 weeks and more than one fifth achieved a 70 percent symptom improvement, according to results of a European study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. This study is the first phase III trial of tocilizumab.
Similar news · Read more »